Equity Profile

CRVS

Corvus Pharmaceuticals, Inc.

Health CareBiotechnology$1.0B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

Expected to be around -$0.14.

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal positive momentum in product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRVS Q2-2026 Earnings Preview

Context

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. With a market cap of $1 billion, the company is part of the health care sector, which is increasingly important as advancements in medical technology and personalized medicine continue to evolve.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-58.69%

Avg Stock Reaction

-2.23%

Last Quarter Recap

In Q1-2026, Corvus reported an EPS of -$0.15, slightly missing analyst expectations. The stock reacted negatively, declining by 5.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Corvus's upcoming earnings, especially given the high implied volatility in the options market. However, the company's recent performance has left some uncertainty.

Bull Case

If Corvus can beat EPS expectations and show signs of revenue growth, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company misses expectations again, it may raise concerns about its viability and lead to further declines in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around -$0.14.

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would signal positive momentum in product development and market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the expected -$0.14?

A beat on EPS could signal improved operational efficiency and investor confidence.

Is there any indication of revenue growth or new partnerships?

Growth in revenue or strategic partnerships could indicate a positive trajectory for the company.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Corvus's potential for a turnaround given its recent focus on innovative treatments, which could lead to unexpected revenue growth.

Supporting Evidence

Options are pricing a 40.2% move, indicating high expectations that may not align with the company's actual performance.

The recent history of EPS surprises shows a mixed track record, suggesting the potential for a positive surprise.

Key Risk

If EPS comes in better than -$0.14, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it may determine the company's ability to regain investor trust after recent misses.

Bull Confirmed If

An EPS of -$0.14 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.15 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±40.2%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±40.2% while CRVS has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

96.0%

Calls (48K)P/C Ratio: 0.69Puts (16K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corvus beats expectations, history suggests the stock could rise by around 2.4%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses again, history suggests a decline of about 6.87%, which could raise serious concerns about its future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials or product development timelines.
2Details on partnerships or collaborations that may impact revenue.
3Management's outlook on market conditions and competitive landscape.
4Insights into cost management and operational efficiency improvements.
5Any guidance on future earnings expectations or strategic initiatives.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

Expected to be around -$0.14.

Revenue Growth

While specific revenue estimates are not available, any growth in revenue would signal positive momentum in product development and market acceptance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-58.69%

Avg Stock Reaction

-2.23%

Last Quarter Recap

In Q1-2026, Corvus reported an EPS of -$0.15, slightly missing analyst expectations. The stock reacted negatively, declining by 5.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Corvus can beat EPS expectations and show signs of revenue growth, it could boost investor confidence and lead to a significant stock price increase.

Bear Case

Conversely, if the company misses expectations again, it may raise concerns about its viability and lead to further declines in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around -$0.14.

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue would signal positive momentum in product development and market acceptance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the expected -$0.14?

A beat on EPS could signal improved operational efficiency and investor confidence.

Is there any indication of revenue growth or new partnerships?

Growth in revenue or strategic partnerships could indicate a positive trajectory for the company.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Corvus's potential for a turnaround given its recent focus on innovative treatments, which could lead to unexpected revenue growth.

Supporting Evidence

Options are pricing a 40.2% move, indicating high expectations that may not align with the company's actual performance.

The recent history of EPS surprises shows a mixed track record, suggesting the potential for a positive surprise.

Key Risk

If EPS comes in better than -$0.14, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it may determine the company's ability to regain investor trust after recent misses.

Bull Confirmed If

An EPS of -$0.14 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.15 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±40.2%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a substantial move, indicating that investors expect significant volatility around the earnings report.

Options are pricing ±40.2% while CRVS has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

96.0%

Calls (48K)P/C Ratio: 0.69Puts (16K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corvus beats expectations, history suggests the stock could rise by around 2.4%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

If the company misses again, history suggests a decline of about 6.87%, which could raise serious concerns about its future.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials or product development timelines.
2Details on partnerships or collaborations that may impact revenue.
3Management's outlook on market conditions and competitive landscape.
4Insights into cost management and operational efficiency improvements.
5Any guidance on future earnings expectations or strategic initiatives.